Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia

International Journal of Hematology

Volumn 96, Issue 1, 2012, Pages 132-135

  Zakrzewski, Dariusz ^a   Seferynska, Ilona ^b   Warzocha, Krzysztof ^b   Hryniewiecki, Tomasz ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Chronic myeloid leukemia; Nilotinib; Pulmonary artery pressure elevation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; ENOXAPARIN; NILOTINIB; THALIDOMIDE;

AGED; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DOSE RESPONSE; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; HUMAN; LUNG ARTERY PRESSURE; MALE; MULTIPLE MYELOMA; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; THROMBOEMBOLISM; TRICUSPID VALVE REGURGITATION;

AGED; ANTINEOPLASTIC AGENTS; ECHOCARDIOGRAPHY, DOPPLER; HUMANS; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PYRIMIDINES;

EID: 84865042051     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1103-0     Document Type: Article

References (12)

1. ® (nilotinib) capsules prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ. 2010.
2. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233-7.
3. Ribeiro AL, Marcolino MS, Bittencourt HN, Barbosa MM. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res. 2008;32:1809-14.
4. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib and sorafenib on mitochondria function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106:153-61.
5. Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Preclinical evaluation of potential nilotinib cardiotoxicity. Leuk Res. 2011;35:631-7.
6. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33(6):861-4.
7. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, lowdose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36:e4-6.
8. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011; 11:30.
9. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967-8.
10. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182:1171-7.
11. Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008;32:232-5.
12. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, Nair D, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27:1485-94. (Pubitemid 43998084)